Total Raised

$58.45M

Investors Count

13

Deal Terms

2

Funding, Valuation & Revenue

7 Fundings

Cepheid has raised $58.45M over 7 rounds.

Cepheid's latest funding round was a Grant for $28M on July 30, 2021.

Cepheid's valuation in November 2016 was $4,000M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

7/30/2021

Grant

$28M

$XXM

0

FY undefined

1

11/5/2016

Acq - P2P

$4,000M

0

FY undefined

10

6/21/2000

IPO

$XXM

$XXM

0

FY undefined

10

1/6/2000

Series C

$XXM

$XXM

0

FY undefined

0

4/13/1998

Series B

$XXM

$XXM

0

FY undefined

0

Date

7/30/2021

11/5/2016

6/21/2000

1/6/2000

4/13/1998

Round

Grant

Acq - P2P

IPO

Series C

Series B

Amount

$28M

$XXM

$XXM

$XXM

Investors

Valuation

$XXM

$4,000M

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

0

0

Start free trial
New call-to-action

Cepheid Deal Terms

2 Deal Terms

Cepheid's deal structure is available for 2 funding rounds, including their Acq - P2P from November 05, 2016.

Round

Acq - P2P

Series B

Funding Date

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

$XXM

Amount Raised

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

Board Voting

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acq - P2P

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

Cepheid Investors

13 Investors

Cepheid has 13 investors. US Department of Health and Human Services invested in Cepheid's Grant funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/30/2021

7/30/2021

1
Grant

Government

DC

11/5/2016

11/5/2016

1
Acq - P2P

Corporation

DC

4/13/1998

1/6/2000

2
Series B, Series C (2000)

Investment Bank

New York

00/00/0000

00/00/0000

Medtronic

Subscribe to see more

Corporation

Minnesota

00/00/0000

00/00/0000

Fujirebio

Subscribe to see more

Corporation

Belgium

First funding

7/30/2021

11/5/2016

4/13/1998

00/00/0000

00/00/0000

Last Funding

7/30/2021

11/5/2016

1/6/2000

00/00/0000

00/00/0000

Investor

Medtronic

Fujirebio

Rounds

1
Grant
1
Acq - P2P
2
Series B, Series C (2000)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Government

Corporation

Investment Bank

Corporation

Corporation

Location

DC

DC

New York

Minnesota

Belgium

Cepheid Acquisitions

2 Acquisitions

Cepheid acquired 2 companies. Their latest acquisition was OncoMark on December 16, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/16/2021

Other

$XXM

$9.9M

Acquired

4

10/3/2014

Subscribe to see more

$XXM

Subscribe to see more

10

Date

12/16/2021

10/3/2014

Investment Stage

Other

Companies

Subscribe to see more

Valuation

$XXM

$XXM

Total Funding

$9.9M

Note

Acquired

Subscribe to see more

Sources

4

10

New call-to-action

Compare Cepheid to Competitors

Mimark

Mimark focuses on the development of diagnostic solutions for gynecological diseases within the healthcare sector. The company provides a diagnostic approach that utilizes gynecological fluids to assist in the diagnosis of gynecological conditions. Their main products include GyLDEC for endometrial cancer diagnosis and GyLDENDO for endometriosis diagnosis, both of which are based on protein biomarker analysis and designed to be less invasive. It was founded in 2021 and is based in Barcelona, Spain.

Ontera

Ontera specializes in the development of silicon nanopore chips and proprietary biochemistry for the life sciences industry. The company's main offerings include tools for the detection and differentiation of single molecules, which are important for point-of-care testing and third generation sequencing. Ontera primarily serves sectors that require diagnostic and sequencing solutions. Ontera was formerly known as Two Pore Guys. It was founded in 2011 and is based in Bangkok, Thailand.

Thermo Fisher Scientific

Thermo Fisher Scientific serves the science sector with a range of products and services. The company offers scientific research tools, biotechnology products, and diagnostic testing equipment, as well as laboratory and pharmaceutical development services. Thermo Fisher Scientific serves the biotech, biopharma, contract development and manufacturing organization (CDMO), lab diagnostics, and industrial and applied sciences sectors. Thermo Fisher Scientific was formerly known as Thermo Electron. It was founded in 2006 and is based in Waltham, Massachusetts.

PerkinElmer

PerkinElmer operates as a provider of technology and service solutions in the laboratory sector, focusing on food, industrial, life sciences, and environmental markets. The company offers a range of products and services, including laboratory technologies for analysis and characterization, atomic spectroscopy, chromatography, and food quality analyzers. PerkinElmer's solutions help customers evaluate the quality and safety of products. It was founded in 1937 and is based in Shelton, Connecticut.

Meterbolic

Meterbolic conducts metabolic health assessments and preventive healthcare within the medical diagnostics sector. The company offers tests that measure insulin response and other metabolic markers to predict the risk of diabetes and other chronic diseases, which can assist in health management. Meterbolic serves individuals seeking health monitoring and those interested in preventive healthcare. It was founded in 2018 and is based in London, United Kingdom.

Color

Color specializes in genetic testing and health services. It focuses on early detection and management of cancer and hereditary diseases. The company offers genetic screenings to assess the risk for hereditary cancer and heart conditions, as well as services to understand medication responses, aiming to facilitate preventative health measures and personalized care plans. Color primarily serves employers, health plans, unions, and clinicians, providing them with tools to manage the health of their populations. Color was formerly known as Color Genomics. It was founded in 2014 and is based in Burlingame, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy. By continuing to use this site you are consenting to these choices.